Skip to main content

Table 2 Characteristics of patients initiating HCV treatment with 2nd-wave DAA-based regimens in 2014–2015, France

From: Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015

 

2014

2015

 

Men

Women

Total

Men

Women

Total

 

%

%

n

%

%

%

n

%

Total

65.9

34.1

8702

100

64.4

35.6

14,650

100

Age group (years)a

  < 30

0.3

0.3

30

0.3

0.8

0.7

112

0.8

 30–39

2.6

1.3

184

2.1

4.3

2.1

519

3.5

 40–49

20.6

9.4

1461

16.8

20.5

9.6

2441

16.7

 50–59

50.1

30.5

3776

43.4

48.2

31.8

6204

42.4

 60–69

18.6

31.0

1985

22.8

17.6

27.1

3068

20.9

 70–79

6.3

22.1

1015

11.7

6.5

21.2

1716

11.7

 80 and over

1.5

5.4

249

2.9

2.1

7.5

585

4.0

Complementary Universal Health insurance (CMUC)a

 Yes

15.5

11.3

1218

14.0

17.3

12.6

2291

15.6

State Medical Assistance (AME)a

 Yes

0.9

1.4

93

1.1

2.1

1.9

298

2.0

Long-term disease status (LTD) for HCVb

 Yes

53.4

56.9

4276

54.6

43.2

48.9

6017

45.3

Previous HCV treatment initiation between 2007 and 2013

 No

52.5

59.8

4786

55.0

72.1

74.9

10,703

73.1

 Yesc

47.5

40.2

3916

45.0

27.9

25.1

3947

26.9

   with PEG-IFN/RBV bitherapy only

72.5

72.1

2833

72.4

81.3

80.6

3200

81.1

   with 1st-wave PIs only

12.6

13.6

506

12.9

9.3

10.9

388

9.8

   with PEG-IFN/RBV bitherapy and 1st-wave PIs

14.9

14.3

575

14.7

9.4

8.5

359

9.1

  1. PEG-IFN Pegylated Interferon α, RBV Ribavirin, 1st- wave PIs first-wave protease inhibitors
  2. aMissing values: in 2014, 2 patients for age, 13 patients for CMUC and AME; in 2015, 5 patients for age
  3. bThis data was available only for beneficiaries of the general insurance scheme
  4. cPrevious HCV treatment initiation with 2nd- wave DAAs in 2013 for 2 patients